These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 36114096)
1. Nab-Paclitaxel for Previously Treated Advanced Non-Small Cell Lung Cancer: Analysis of Safety and Efficacy for Patients With Renal Impairment. Yoneshima Y; Morita S; Ando M; Nakamura A; Iwasawa S; Yoshioka H; Goto Y; Takeshita M; Harada T; Hirano K; Oguri T; Kondo M; Miura S; Hosomi Y; Kato T; Kubo T; Kishimoto J; Yamamoto N; Nakanishi Y; Okamoto I Clin Lung Cancer; 2022 Nov; 23(7):585-592. PubMed ID: 36114096 [TBL] [Abstract][Full Text] [Related]
2. Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment. Langer CJ; Hirsh V; Ko A; Renschler MF; Socinski MA Clin Lung Cancer; 2015 Mar; 16(2):112-20. PubMed ID: 25572008 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial. Kogure Y; Iwasawa S; Saka H; Hamamoto Y; Kada A; Hashimoto H; Atagi S; Takiguchi Y; Ebi N; Inoue A; Kurata T; Okamoto I; Yamaguchi M; Harada T; Seike M; Ando M; Saito AM; Kubota K; Takenoyama M; Seto T; Yamamoto N; Gemma A Lancet Healthy Longev; 2021 Dec; 2(12):e791-e800. PubMed ID: 36098037 [TBL] [Abstract][Full Text] [Related]
5. Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. Yoneshima Y; Morita S; Ando M; Miura S; Yoshioka H; Abe T; Kato T; Kondo M; Hosomi Y; Hotta K; Yamamoto N; Kishimoto J; Nakanishi Y; Okamoto I Clin Lung Cancer; 2017 Jan; 18(1):100-103. PubMed ID: 28341108 [TBL] [Abstract][Full Text] [Related]
6. A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Hattori Y; Kono Y; Itoh S; Inoue T; Urata Y; Kawa Y; Tohnai R; Kumagai T; Nishino K; Uozumi R; Morita S; Negoro S; Imamura F; Satouchi M BMC Cancer; 2020 Feb; 20(1):115. PubMed ID: 32046667 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of weekly nab-paclitaxel for previously treated advanced non-small cell lung cancer: Kumamoto thoracic oncology study group (KTOSG) trial 1301. Sakata S; Saeki S; Okamoto I; Otsubo K; Komiya K; Morinaga R; Yoneshima Y; Koga Y; Enokizu A; Kishi H; Hirosako S; Yamaguchi E; Aragane N; Fujii S; Harada T; Iwama E; Semba H; Nakanishi Y; Kohrogi H Lung Cancer; 2016 Sep; 99():41-5. PubMed ID: 27565912 [TBL] [Abstract][Full Text] [Related]
8. A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol. Kogure Y; Saka H; Takiguchi Y; Atagi S; Kurata T; Ebi N; Inoue A; Kubota K; Takenoyama M; Seto T; Kada A; Yamanaka T; Ando M; Yamamoto N; Gemma A; Ichinose Y Clin Lung Cancer; 2018 Sep; 19(5):e711-e715. PubMed ID: 29861395 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer. Satouchi M; Okamoto I; Sakai H; Yamamoto N; Ichinose Y; Ohmatsu H; Nogami N; Takeda K; Mitsudomi T; Kasahara K; Negoro S Lung Cancer; 2013 Jul; 81(1):97-101. PubMed ID: 23545279 [TBL] [Abstract][Full Text] [Related]
10. A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer. Okuma Y; Hosomi Y; Takahashi S; Nakahara Y; Watanabe K; Nagamata M; Takagi Y; Mikura S Cancer Chemother Pharmacol; 2016 Aug; 78(2):383-8. PubMed ID: 27339149 [TBL] [Abstract][Full Text] [Related]
11. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study. Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K; Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107 [TBL] [Abstract][Full Text] [Related]
13. A dose finding study of weekly and every-3-week nab-Paclitaxel followed by carboplatin as first-line therapy in patients with advanced non-small cell lung cancer. Socinski MA; Manikhas GM; Stroyakovsky DL; Makhson AN; Cheporov SV; Orlov SV; Yablonsky PK; Bhar P; Iglesias J J Thorac Oncol; 2010 Jun; 5(6):852-61. PubMed ID: 20521351 [TBL] [Abstract][Full Text] [Related]
14. nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial. Gridelli C; Chen T; Ko A; O'Brien ME; Ong TJ; Socinski MA; Postmus PE Drug Des Devel Ther; 2018; 12():1445-1451. PubMed ID: 29872267 [TBL] [Abstract][Full Text] [Related]
15. ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). Morgensztern D; Cobo M; Ponce Aix S; Postmus PE; Lewanski CR; Bennouna J; Fischer JR; Juan-Vidal O; Stewart DJ; Fasola G; Ardizzoni A; Bhore R; Wolfsteiner M; Talbot DC; Jin Ong T; Govindan R; On Behalf Of The Abound L Investigators Cancer; 2018 Dec; 124(24):4667-4675. PubMed ID: 30383906 [TBL] [Abstract][Full Text] [Related]
16. A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. Villaruz LC; Cobo M; Syrigos K; Mavroudis D; Zhang W; Kim JS; Socinski MA Lung Cancer; 2019 Oct; 136():52-56. PubMed ID: 31445354 [TBL] [Abstract][Full Text] [Related]
17. Phase II study of carboplatin/nab-paclitaxel/atezolizumab combination therapy for advanced nonsquamous non-small cell lung cancer patients with impaired renal function: RESTART trial. Shiraishi Y; Kishimoto J; Shimose T; Toi Y; Sugawara S; Okamoto I BMC Cancer; 2022 Sep; 22(1):964. PubMed ID: 36076179 [TBL] [Abstract][Full Text] [Related]
18. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed. Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. Chen YM; Shih JF; Lee CS; Chen MC; Lin WC; Tsai CM; Perng RP Lung Cancer; 2003 Feb; 39(2):209-14. PubMed ID: 12581575 [TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer. Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I Lung Cancer; 2018 Nov; 125():136-141. PubMed ID: 30429011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]